Research shows that binge-eating disorder, which is more common than other eating disorders such as bulimia and anorexia, affects more women than men. Experts say that despite popular opinion that binge eating is a mood or phase, it is a serious issue that needs to be addressed. Regence BlueCross BlueShield’s executive medical director Dr. Amy Khan states that eating disorders often represent serious mental health conditions.
Khan explains that eating disorders are serious ailments that can impact an individual’s social, emotional and physical functioning. This is in addition to affecting their cardiovascular health and causing gastrointestinal issues. The disorders are also known to affect a person’s metabolic and neurological function and have been associated with obesity.
Symptoms of binge-eating disorder include:
A survey conducted last year demonstrated worsening symptoms and an increase in eating disorders throughout the pandemic. Data shows that there was a 30% increase in bulimia nervosa, with binge-eating disorder also reporting significant increases. Reports from the National Eating Disorders Association also show that help-line calls also rose by 40% since March 2020.
Khan stated that saying that people were going through a phase or that they were choosing abnormal behaviors associated with eating were misconceptions, noting that being afflicted with these disorders wasn’t a moral failing. She added that increased levels of anxiety and stress could contribute to the condition’s development, along with excessive dieting and a family history of the disorders.
In addition to this, Khan explained that individuals suffering from binge eating disorder often ate large amounts of food in two hours, weekly for a few months, adding that most exhibited a lack of control and would eat more quickly than normal, which left most feeling uncomfortable sometimes. Khan asserted that individuals suffering from this disorder also ate large amounts of food even when they weren’t hungry, which aligns with symptoms mentioned above.
If you or a loved one is dealing with eating disorders such as binge eating, consulting with a physician or eating-disorder specialist or attending a support group as virtual interventions may be of help. If you require immediate assistance, you can use the 1-800-931-2237 National Eating Disorder help line to get help.
Companies such as Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) are also engaged in research to develop effective remedies for binge-eating disorder, so there is hope for the millions afflicted by this condition.
NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at https://ibn.fm/TRYPF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
The global market for brain tumor treatments is experiencing significant transformation powered by advances in…
A team of researchers has developed a “cost-effective” and simple blood test with the potential…
Nutriband’s AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible…
Strategic partnerships embrace opportunities to foster innovation, streamline processes and ultimately improve the lives of…
Adageis provides clinics and medical groups with AI-powered tools to track financial outcomes tied to…
Approximately 65% of patients diagnosed with melanoma are unresponsive to immunotherapy. New research suggests that…